Insider trading

Period: 120 months Stock: BHC Role: Other officers × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

34 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

34 decisions over 120 months Remove this filter
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

34 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

34 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
34 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
34 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

34 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
19 Aug 2026
Lenar Aimee J. President, US Pharma
Sold on a plan
$258.89K 36,827 at 7.03
9.9%
Planned (10b5-1)
3 Mar 2026
Carson Seana EVP, General Counsel
Sold on a plan
$25.50K 4,420 at 5.77
0.7%
Planned (10b5-1)
2 Mar 2026
Carson Seana EVP, General Counsel
Sold on a plan
$39.63K 6,856 at 5.78
0.9%
Planned (10b5-1)
27 Feb 2026
Carson Seana EVP, General Counsel
Sold on a plan
$49.91K 8,388 at 5.95
1.0%
Planned (10b5-1)
8 Sep 2025
Carson Seana EVP, General Counsel
Sold on a plan
$97.73K 13,370 at 7.31
2.6%
Planned (10b5-1)
2 Dec 2024
Carson Seana EVP, General Counsel
Sold on a plan
$3.67K 440 at 8.35
0.1%
Planned (10b5-1)
6 Sep 2024
Carson Seana EVP, General Counsel
Sold on a plan
$83.03K 13,370 at 6.21
3.0%
Planned (10b5-1)
4 Mar 2024
Carson Seana EVP, General Counsel
Sold on a plan 4×
$61.87K 6,313 at 9.80
1.2%
Planned (10b5-1)
5 Dec 2023
Carson Seana EVP, General Counsel
Sold on a plan
$1.62K 220 at 7.38
0.1%
Planned (10b5-1)
6 Nov 2023
Carson Seana EVP, General Counsel
Sold on a plan
$327.23 43 at 7.61
0.0%
Planned (10b5-1)
6 Sep 2023
Carson Seana EVP, General Counsel
Sold on a plan
$55.35K 6,685 at 8.28
1.7%
Planned (10b5-1)
28 Feb 2023
Carson Seana EVP, General Counsel
Sold, plan not stated
$2.72K 292 at 9.32
0.1%
14 Apr 2022
Spurr Robert U.S. President-Pharma Business
Sold, plan not stated
$35.39K 1,595 at 22.19
1.7%
15 Mar 2022
Spurr Robert U.S. President-Pharma Business
Sold, plan not stated
$107.58K 4,846 at 22.20
5.0%
8 Mar 2022
Gordon Joseph F Pres&Co-Head Bausch&Lomb/Int'l
Sold, plan not stated
$84.62K 3,889 at 21.76
4.0%
2 Mar 2022
Gordon Joseph F Pres&Co-Head Bausch&Lomb/Int'l
Sold, plan not stated
$258.87K 11,077 at 23.37
9.9%
2 Mar 2022
Spurr Robert U.S. President-Pharma Business
Sold, plan not stated
$37.28K 1,595 at 23.37
2.4%
1 Mar 2022
Gordon Joseph F Pres&Co-Head Bausch&Lomb/Int'l
Sold, plan not stated
$150.97K 6,338 at 23.82
5.3%
15 Feb 2022
Spurr Robert U.S. President-Pharma Business
Sold, plan not stated
$81.34K 3,251 at 25.02
5.1%
18 Jan 2022
Spurr Robert U.S. President-Pharma Business
Sold, plan not stated
$86.57K 3,251 at 26.63
4.9%
2 Jun 2021
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Sold, plan not stated
$3.86M 121,198 at 31.83
42.1%
4 Dec 2020
Humphries William D. President, Ortho-Dermatologics
Sold, plan not stated
$2.27M 114,055 at 19.87
32.7%
27 Nov 2020
Humphries William D. President, Ortho-Dermatologics
Sold, plan not stated
$268.21K 13,663 at 19.63
5.5%
24 Nov 2020
Humphries William D. President, Ortho-Dermatologics
Sold, plan not stated
$425.20K 21,658 at 19.63
8.4%
23 Nov 2020
Humphries William D. President, Ortho-Dermatologics
Sold, plan not stated
$29.12K 1,483 at 19.63
0.6%
8 Sep 2020
Humphries William D. President, Ortho-Dermatologics
Sold, plan not stated
$91.64K 5,667 at 16.17
2.4%
10 Mar 2020
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Bought
$80.11K 4,390 at 18.25
5.0%
First buy on file
19 Aug 2019
McKenna Mark C. President, Salix
Sold, plan not stated
$235.22K 10,773 at 21.83
34.2%
16 Aug 2019
Humphries William D. President, Ortho-Dermatologics
Bought
$650.14K 30,703 at 21.18
26.2%
First buy on file
12 Aug 2019
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Sold, plan not stated
$76.73K 3,418 at 22.45
6.3%
11 Jul 2019
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Sold, plan not stated
$98.45K 3,968 at 24.81
6.0%
14 Dec 2018
APPIO THOMAS Pres&Co-Head Bausch&Lomb/Int'l
Bought
$584.02K 25,440 at 22.96
24.6%
First buy on file
16 Oct 2018
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Sold, plan not stated
$115.82K 4,542 at 25.50
8.1%
15 Oct 2018
ACKERMANN CHRISTINA EVP AND GENERAL COUNSEL
Sold, plan not stated
$382.48K 15,404 at 24.83
21.6%
Showing 1–34 of 34.